Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease

MLA

Takahiro Amano, et al. “Selection of Anti-Cytokine Biologics by Pretreatment Levels of Serum Leucine-Rich Alpha-2 Glycoprotein in Patients with Inflammatory Bowel Disease.” Scientific Reports, vol. 14, no. 1, Nov. 2024, pp. 1–11. EBSCOhost, https://doi.org/10.1038/s41598-024-80285-6.

APA

Takahiro Amano, Takeo Yoshihara, Shinichiro Shinzaki, Yuko Sakakibara, Takuya Yamada, Naoto Osugi, Satoshi Hiyama, Yoko Murayama, Koji Nagaike, Hideharu Ogiyama, Toshio Yamaguchi, Yuki Arimoto, Ichizo Kobayashi, Shoichiro Kawai, Satoshi Egawa, Takashi Kizu, Masato Komori, Yuri Tsujii, Akiko Asakura, … Tetsuo Takehara. (2024). Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease. Scientific Reports, 14(1), 1–11. https://doi.org/10.1038/s41598-024-80285-6

Chicago

Takahiro Amano, Takeo Yoshihara, Shinichiro Shinzaki, Yuko Sakakibara, Takuya Yamada, Naoto Osugi, Satoshi Hiyama, et al. 2024. “Selection of Anti-Cytokine Biologics by Pretreatment Levels of Serum Leucine-Rich Alpha-2 Glycoprotein in Patients with Inflammatory Bowel Disease.” Scientific Reports 14 (1): 1–11. doi:10.1038/s41598-024-80285-6.